Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Dachs LR, Gaisán CM, Bustamante G, López SG, García EG, Persona EP, González-Calle V, Auzmendi MS, Pérez JMA, González Montes Y, Ríos Tamayo R, de Miguel Llorente D, Bernal LP, Mayol AS, Caro CC, Grande M, Fernández-Nistal A, Naves A, Miguel EMOS. Dachs LR, et al. Among authors: gonzalez calle v. Leuk Lymphoma. 2023 Nov-Dec;64(11):1847-1856. doi: 10.1080/10428194.2023.2240922. Epub 2023 Aug 4. Leuk Lymphoma. 2023. PMID: 37539698
Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study.
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez-Persona E, González-Calle V, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández-Nistal A, Naves A, Rosiñol L. Ocio EM, et al. Among authors: gonzalez calle v. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):e341-e347. doi: 10.1016/j.clml.2023.07.006. Epub 2023 Jul 15. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37517875 Free article.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Puertas B, González-Calle V, Sureda A, Moreno MJ, Oriol A, González E, Rosiñol L, López J, Escalante F, Martínez-Lopez J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, González-Rodríguez AP, Dourdil V, De Arriba F, González S, Pérez-de-Oteyza J, Hernández MT, García-Mateo A, Bargay J, Bladé J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV. Puertas B, et al. Haematologica. 2023 Oct 1;108(10):2753-2763. doi: 10.3324/haematol.2022.282490. Haematologica. 2023. PMID: 37102598 Free PMC article. Clinical Trial.
Smoldering Multiple Myeloma: Who and When to Treat.
Mateos MV, González-Calle V. Mateos MV, et al. Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):716-722. doi: 10.1016/j.clml.2017.06.022. Epub 2017 Jun 23. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28709797 Review.
[No title available]
[No authors listed] [No authors listed] PMID: 36164154
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.
González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV. González-Calle V, et al. Leukemia. 2016 Oct;30(10):2026-2031. doi: 10.1038/leu.2016.123. Epub 2016 May 2. Leukemia. 2016. PMID: 27133826
[No title available]
[No authors listed] [No authors listed] PMID: 36164155
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060 Free article.
Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients.
Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grząśko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Valls JD, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski Ł, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Mazur P, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozłowska I, Goldberg SL, Czepiel J, Długosz-Danecka M, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Vesole DH. Goldman-Mazur S, et al. Leuk Lymphoma. 2020 Aug;61(8):1885-1893. doi: 10.1080/10428194.2020.1749605. Epub 2020 Apr 19. Leuk Lymphoma. 2020. PMID: 32306794
Multiple myeloma with t(11;14): impact of novel agents on outcome.
Puertas B, González-Calle V, Sobejano-Fuertes E, Escalante F, Rey-Bua B, Padilla I, García-Sanz R, Puig N, Gutiérrez NC, Mateos MV. Puertas B, et al. Blood Cancer J. 2023 Mar 20;13(1):40. doi: 10.1038/s41408-023-00807-9. Blood Cancer J. 2023. PMID: 36935422 Free PMC article.
58 results